试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic MalignanciesCTIS2022-501797-19-00AvenCell Europe GmbH60
进行中（未招募）
1 期
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumorsgastroesophageal junction [GEJ] carcinoma, Non-small cell lung cancer (NSCLC), Gastric cancer, Cervical cancer, Ovarian cancer, Endometrial cancer, Malignant ovarian GCT with the exception of pure teratomas, Malignant testicular germ cell tumor (GCT) with the exception of pure teratomas, Gastroesophageal junction carcinoma, Malignant extragonadal GCT with the exception of pure teratomas or tumors with primaries arising from the central nervous system (CNS)MedDRA version: 21.1Level: LLTClassification code: 10043338Term: Testicular malignant germ cell tumor NOS Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10017758Term: Gastric cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: HLTClassification code: 10033222Term: Ovarian germ cell neoplasms malignant Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10066354Term: Adenocarcinoma of the gastroesophageal junction Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10073060Term: Extragonadal primary germ cell tumor Class: 10029104CTIS2022-500094-14-00Seagen Inc.254
招募中
1 期
Study of SGN-PDL1V in Advanced Solid TumorsCTIS2023-506604-18-00Seagen Inc.322
招募中
1 期
Study of safety, tolerability and efficacy of DFV890 in participants with myeloid diseasesCTIS2022-501406-36-00ovartis Pharma AG80
招募中
1 期
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)CTIS2024-513329-22-00Kyverna Therapeutics Inc.32